Novartis PPA litigation
This article was originally published in The Tan Sheet
Executive Summary
California jury clears Novartis of charges that the firm concealed material facts about the presence of phenylpropanolamine (PPA) in cough/cold products, firm announces Jan. 23. The jury also rejects allegations that Triaminicin and Tavist D "were unsafe products with inadequate warnings," Novartis says. Firm notes a New Jersey jury cleared the firm of similar charges in a case one week earlier. California, New Jersey verdicts are first in a number of cases filed against consumer health product manufacturers concerning the use of PPA in cough/cold products. PPA was voluntarily removed from the market in November 2000 at the request of FDA (1"The Tan Sheet" Nov. 13, 2000, p. 4)...